The drug discovery company says it has conducted the latest study for a treatment on a group of 130 individuals suffering from acneic skin, showing that it significantly reduced the amount of acne and associated symptoms within four weeks.
The Phase II proof of concept study was begun in July 2007 and was conducted in Germany on a group of 130 subjects and carried out in a randomised blinded manner using two different formulations.
Formula combines bacteriostatic agent
The first formula to be examined was SYN 0126, which the company says is designed for cosmetic preparations, while the other was SYN 0126 combined with a bacteriostatic agent SYN 0091, which is appropriate for both cosmetic and soap formulations.
The study had both positive and negative controls and the subjects used the treatment over an eight week course.
The results showed that the combination, SYN 0091 and SYN 0126 treatment was more effective in treating acne and its associated symptoms, specifically showing a reduction in inflammatory and non-inflammatory spots from week two to the end of the study.
Treatment improved severity grade by 38 per cent
By the end of the treatment, the study showed that this formula had reduced the total number of spots by 27 per cent, and that the overall acne severity grade had been reduced by 38 per cent, while reductions for SYN 0126 on its own were 12 per cent and 24 per cent respectively.
The company says that following these results it is now actively seeking an appropriate marketing agreement for the formula containing the two compounds.
"The positive results from this study confirm the progress that the company is making in identifying compounds that can be developed as novel interventions for the treatment of acne," said Stephen Jones Syntopix CEO.
